The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

Diabetic macular edema (DME) occurs when fluid accumulates behind the macula, the part of your retina that processes central vision. DME can occur at any stage of diabetic retinopathy (DR). However, ...

– Faricimab given every eight weeks and at personalized dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies ...

Diabetic macular edema (DME) is a diabetes complication that can cause vision loss or blindness. It happens when high blood sugar damages the eye’s blood vessels, causing fluid buildup in the macula.

Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Brolucizumab (Beovu) proved noninferior to aflibercept (Eylea) for visual outcomes among patients with diabetic macular edema (DME), the phase III KINGFISHER trial showed. In over 500 patients with ...

In April 2017, Lucentis 0.3 mg became, and remains, the first and only FDA-approved medicine to treat all forms of diabetic retinopathy in people with or without diabetic macular edema (DME), a ...

Peripheral edema, or swelling, has long been associated with certain conditions and research continues regarding causes and treatments for the swelling that occurs when fluid collects in tissue.

Faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies ...